A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants Who Have Obesity or Are Overweight
Latest Information Update: 28 Mar 2025
At a glance
- Drugs RAY 1225 (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Guangdong Raynovent Biotech
- 28 Mar 2025 New trial record